The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

NARecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions
AML
Interventions
PROCEDURE

allo-HSCT

allo-HSCT from any type of donor

Trial Locations (1)

Unknown

RECRUITING

National Research Center for Hematology, Moscow

All Listed Sponsors
collaborator

Botkin Hospital

OTHER

collaborator

St. Petersburg State Pavlov Medical University

OTHER

collaborator

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

OTHER

collaborator

Federal Research Clinical Center of Federal Medical & Biological Agency, Russia

OTHER_GOV

collaborator

Regional Clinical Hospital of Yaroslavl

UNKNOWN

collaborator

Nizhny Novgorod regional clinical hospital named after N.A.Semashko

UNKNOWN

collaborator

Clinical hospital №1 of Sverdlovsk region

UNKNOWN

collaborator

"Irkutsk regional clinical hospital, winner of the Mark of the Honor award"

UNKNOWN

collaborator

The Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood T

OTHER_GOV

lead

National Research Center for Hematology, Russia

NETWORK